Kinase Inhibitor class drugs

50 results

  • alecensa

    (ALECTINIB HYDROCHLORIDE)
    Genentech, Inc.
    ALECENSA is indicated for the adjuvant treatment of adults with resected ALK-positive non-small cell lung cancer (NSCLC), and for the treatment of adult patients with metastatic ALK-positive NSCLC, both as detected by an FDA-approved test.
    Medication Details
    Drug Interactions

  • alunbrig

    (brigatinib)
    Takeda Pharmaceuticals America, Inc.
    ALUNBRIG is indicated for the treatment of adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC), confirmed by an FDA-approved test.
    Medication Details
    Drug Interactions

  • augtyro

    (repotrectinib)
    E.R. Squibb & Sons, L.L.C.
    AUGTYRO is indicated for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) and for patients aged 12 and older with NTRK gene fusion-positive solid tumors that are advanced or metastatic, or where surgery poses severe risk, and have limited treatment options.
    Medication Details
    Drug Interactions

  • ayvakit

    (avapritinib)
    Blueprint Medicines Corporation
    AYVAKIT® is indicated for adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) with PDGFRA exon 18 mutations, advanced systemic mastocytosis (AdvSM), and indolent systemic mastocytosis (ISM). It is not recommended for patients with platelet counts below 50 × 10⁹/L.
    Medication Details
    Drug Interactions

  • balversa

    (Erdafitinib)
    Janssen Products LP
    BALVERSA is indicated for treating adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with FGFR3 genetic alterations, following progression on at least one prior systemic therapy. Selection of patients must utilize an FDA-approved companion diagnostic. It is not recommended for those eligible for PD-1 or PD-L1 inhibitors.
    Medication Details
    Drug Interactions

  • cabometyx

    (cabozantinib)
    Exelixis, Inc.
    CABOMETYX is indicated for advanced renal cell carcinoma (RCC), both as a monotherapy and in combination with nivolumab. It is also used for hepatocellular carcinoma (HCC) after sorafenib treatment and for locally advanced or metastatic differentiated thyroid cancer (DTC) in patients 12 and older who are radioactive iodine-refractory.
    Medication Details
    Drug Interactions

  • cosela

    (trilaciclib)
    G1 Therapeutics, Inc.
    COSELA is indicated to reduce the incidence of chemotherapy-induced myelosuppression in adults prior to platinum/etoposide or topotecan regimens for extensive-stage small cell lung cancer (ES-SCLC).
    Medication Details
    Drug Interactions

  • cotellic

    (COBIMETINIB)
    Genentech, Inc.
    COTELLIC® is indicated for adult patients with unresectable or metastatic melanoma harboring BRAF V600E or V600K mutations, in combination with vemurafenib. It is also indicated as a single agent for the treatment of adult patients with histiocytic neoplasms.
    Medication Details
    Drug Interactions

  • everolimus

    (Everolimus)
    ENDO USA, Inc.
    Everolimus Tablets are indicated for postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer; adults with progressive neuroendocrine tumors (pancreatic, gastrointestinal, or lung origin); advanced renal cell carcinoma after prior treatment failure; renal angiomyolipoma associated with tuberous sclerosis complex; and subependymal giant cell astrocytoma in TSC patients.
    Medication Details
    Drug Interactions